OverviewSuggest Edit

Aravive is a clinical-stage biotechnology company developing therapies for solid tumors and hematologic malignancies. It develops AVB-S6-500, a GAS6 binding protein and AXL decoy receptor for the treatment of ovarian cancer, renal cell carcinoma, acute myeloid leukemia, triple-negative breast cancer, and pancreatic cancer. The company was formed as a result of a merger between Versartis and Aravive Biologics.
TypePublic
Founded2008
HQHouston, TX, US
Websitearavive.com

Latest Updates

Employees (est.) (Dec 2019)16(+15%)
Revenue (FY, 2020)$5.7 M(+20%)
Share Price (Sept 2021)$3.8(-2%)
Cybersecurity ratingAMore

Key People/Management at Aravive

Gail McIntyre

Gail McIntyre

Chief Executive Officer & Board Director
Vinay Shah

Vinay Shah

Chief Financial Officer
Reshma Rangwala

Reshma Rangwala

Chief Medical Officer
Fred Eshelman

Fred Eshelman

Chairman of the Board
Elisabeth Gardiner

Elisabeth Gardiner

Vice President of Translational Medicine
Amato Giaccia

Amato Giaccia

Director
Show more

Aravive Office Locations

Aravive has an office in Houston
Houston, TX, US (HQ)
3730 Kirby Dr #1200
Show all (1)

Aravive Financials and Metrics

Aravive Revenue

Aravive's revenue was reported to be $5.69 m in FY, 2020
USD

Revenue (Q1, 2021)

256.0k

Net income (Q1, 2021)

(8.0m)

EBIT (Q1, 2021)

(8.0m)

Market capitalization (14-Sept-2021)

77.7m

Closing stock price (14-Sept-2021)

3.8

Cash (31-Mar-2021)

78.7m

EV

7.2m
Aravive's current market capitalization is $77.7 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

40.0m1.4m4.8m5.7m

Revenue growth, %

(97%)247%

General and administrative expense

29.9m27.4m13.7m13.1m

R&D expense

94.6m11.1m12.8m17.6m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.7m3.1m256.0k

General and administrative expense

4.9m6.0m5.2m4.6m3.3m3.2m4.0m3.2m2.7m2.4m

R&D expense

3.6m3.4m1.0m2.8m3.6m3.8m3.5m2.5m5.1m5.9m

Operating expense total

8.5m9.4m6.2m7.4m6.9m7.0m10.3m5.7m10.7m8.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

81.1m57.0m65.1m60.5m

Prepaid Expenses

562.0k1.0m3.1m1.1m

Current Assets

81.7m58.0m68.2m61.7m

PP&E

798.0k32.0k1.8m526.0k
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(85.0m)(76.3m)(18.2m)(30.5m)

Depreciation and Amortization

311.0k1.1m498.0k1.8m

Accounts Payable

142.0k(1.7m)652.0k1.4m

Cash From Operating Activities

(116.3m)(29.3m)(17.1m)(12.2m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(9.0m)(18.8m)(25.4m)(4.7m)(7.7m)(13.9m)(10.8m)(15.8m)(26.5m)(8.0m)

Depreciation and Amortization

119.0k236.0k975.0k126.0k248.0k373.0k125.0k1.2m1.6m240.0k

Accounts Payable

(690.0k)(695.0k)(1.2m)942.0k284.0k1.9m110.0k(177.0k)615.0k443.0k

Cash From Operating Activities

(8.0m)(15.3m)(20.5m)(1.4m)(8.6m)(12.0m)(4.5m)(10.1m)(16.4m)(10.0m)
USDFY, 2017

Revenue/Employee

593.5k

Financial Leverage

1.1 x
Show all financial metrics

Aravive Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Aravive Online and Social Media Presence

Embed Graph

Aravive News and Updates

Aravive to Participate in Fireside Chat at H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., …

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel

Aravive Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

HOUSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced recent corporate updates and financial results for the second quarter ended June 30, 2021.

Aravive to Participate in Fireside Chat at 2021 BTIG Biotechnology Conference

HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., C…

Aravive Achieves Second Development Milestone from 3D Medicines

Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial fo…

Aravive to Participate in Fireside Chat at 2021 William Blair Biotech Focus Conference

HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., C…
Show more

Aravive Blogs

Manager/Senior Manager, Finance and Accounting

Summary of Position: The successful candidate will be remotely based from the San Diego, CA area or located in our Morrisville, NC office. You will have responsibility over a combination of financial accounting/reporting and financial planning/analysis.  We are looking for an accounting manager who …

Aravive Reports First Quarter 2021 Financial Results and Announces Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer First patient dosed in registrational Phase 3 trial of AVB-500 in platinum resistant ovarian cancer; on track to conduct interim analysis in first

Director/Senior Director, Data Sciences (Medical Writing)

Summary of Position: The successful candidate will be a strong scientist with biopharmaceutical experience in oncology who can collaborate with members of cross-functional teams to prepare (or oversee preparation by contract service providers) high-quality protocols, protocol amendments, investigato…

Senior Director, Clinical Operations (Europe)

Summary of Position: This position has responsibility for strategic and operational leadership relating to the direction, planning execution, and conduct of clinical trials in Europe. The successful candidate will provide day to day management of clinical studies being conducted in Europe, managing …

Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020 Content Import Tue, 11/10/2020 - 16:05 Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020 Nov 10, 2020 This release is a ba…

Senior Manager, Clinical Supply Chain

Summary of Position: The successful candidate will be responsible for managing and maintaining the sample management infrastructure and managing global drug and sample shipments on a set timeline. Work will include but is not limited to overseeing daily operations of 3rd party vendors, preparing for…
Show more

Aravive Frequently Asked Questions

  • When was Aravive founded?

    Aravive was founded in 2008.

  • Who are Aravive key executives?

    Aravive's key executives are Gail McIntyre, Vinay Shah and Reshma Rangwala.

  • How many employees does Aravive have?

    Aravive has 16 employees.

  • What is Aravive revenue?

    Latest Aravive annual revenue is $5.7 m.

  • What is Aravive revenue per employee?

    Latest Aravive revenue per employee is $355.3 k.

  • Who are Aravive competitors?

    Competitors of Aravive include Molecular Templates, Affigen and Ionova Life Science.

  • Where is Aravive headquarters?

    Aravive headquarters is located at 3730 Kirby Dr #1200, Houston.

  • Where are Aravive offices?

    Aravive has an office in Houston.

  • How many offices does Aravive have?

    Aravive has 1 office.